406711-15-7

Basic information

• Product Name: 2-Butenoicacid,4-(2-furanyl)-2-hydroxy-4-oxo-,methylester(9CI)
• Synonyms: 2-Butenoicacid,4-(2-furanyl)-2-hydroxy-4-oxo-,methylester(9CI)
• CAS NO: 406711-15-7
• Molecular Formula: C9H8O5
• Molecular Weight: 0
• Product Categories: KETONE
• Mol File: 406711-15-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Butenoicacid,4-(2-furanyl)-2-hydroxy-4-oxo-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butenoicacid,4-(2-furanyl)-2-hydroxy-4-oxo-,methylester(9CI)(406711-15-7)
• EPA Substance Registry System: 2-Butenoicacid,4-(2-furanyl)-2-hydroxy-4-oxo-,methylester(9CI)(406711-15-7)

Safety Data

• Hazardous Substances Data: 406711-15-7(Hazardous Substances Data)

Upstream product

• 1192-62-7 1-(2-furyl)-1-ethanone 
• 95-92-1 oxalic acid diethyl ester 

Relevant articles and documents

Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators

NMDA receptors are tetrameric complexes composed of GluN1 and GluN2A-D subunits that mediate a slow Ca2+-permeable component of excitatory synaptic transmission. NMDA receptors have been implicated in a wide range of neurological diseases and thus represent an important therapeutic target. We herein describe a novel series of pyrrolidinones that selectively potentiate only NMDA receptors that contain the GluN2C subunit. The most active analogues tested were over 100-fold selective for recombinant GluN2C-containing receptors over GluN2A/B/D-containing NMDA receptors as well as AMPA and kainate receptors. This series represents the first class of allosteric potentiators that are selective for diheteromeric GluN2C-containing NMDA receptors.

NMDA RECEPTOR MODULATORS AND USES RELATED THERETO

This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C subunit-selective NMDA potentiators. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiments, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof. In certain embodiments, the disclosure relates to methods of treating or preventing nervous system disorders comprising administering an effective amount of a composition comprising compound disclosed herein to a subject in need thereof.

INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS MALATE SYNTHASE, METHODS OF MARKING AND USES THEREOF

The present invention provides aryl- or heteroaryl- diketo acid compounds effective to inhibit an activity of a Mycobacterial malate synthase enzyme or to inhibit a malate synthase activity in other bacteria having the enzyme. The compounds may be phenyl-